AVITA Medical Stock

AVITA Medical Gross Margin

The Gross Margin of AVITA Medical (RCEL) as of Aug 17, 2026 is 86.60 %. In the previous year, Gross Margin was 84.93 % — a change of 1.98% (higher).

Gross Margin

86.60 %

YoY

1.98%

Last updated:

Gross Margin of AVITA Medical is 2026 86.60 % . Gross Margin of AVITA Medical was 2025 84.93 % . It decreases by 1.98% higher compared to the previous year.

For AVITA Medical, the gross margin of 86.6% is up versus 80.4% a few years ago.

Access this data via the Eulerpool API
Get Free API Key

AVITA Medical Stock analysis

What does AVITA Medical do? AVITA Medical Inc is a company in the field of regenerative medicine that focuses on the development and marketing of innovative therapy products for the treatment of burns, chronic wounds, and skin defects. The company was founded in 1998 and is headquartered in Valencia, California. AVITA Medical Inc began with research in the field of regenerative medicine at the University of Western Australia, where the company developed its patented technology known as ReNovaCell. This technology allows for the extraction and cultivation of cells from a small area of skin to create a solution that contains the patient's own skin tissue on a large scale. AVITA Medical Inc's business model is based on the development and marketing of regenerative therapy products based on ReNovaCell technology. The company focuses on commercializing products that enable fast, safe, and effective treatment of burns, chronic wounds, and skin defects. AVITA Medical Inc operates in two main segments: regenerative medicine and aesthetic medicine. In regenerative medicine, the company offers a wide range of products based on ReNovaCell technology, including ReCell, a unique autologous cell therapy for rapid burn treatment, Kelo-Cote, a silicone gel formulation for scar treatment, and therapy-complementary wound treatments. In aesthetic medicine, the company distributes a variety of products under the brand RestoreSkin, which focuses on improving skin health and aesthetic appearance, including pore refinement, pigment reduction, and wrinkle reduction. AVITA Medical Inc has established itself as a leading provider of regenerative therapy products. The company has a strong presence both in the US and internationally and is actively advocating for the advancement of regenerative medicine. By developing innovative products that enable fast and effective treatment of skin defects, AVITA Medical Inc will continue to be a key player in regenerative medicine in the future. AVITA Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVITA Medical stock

Gross Margin of AVITA Medical is 86.60 % in 2026.

Gross Margin of AVITA Medical changed from 84.93 % to 86.60 %, representing a 1.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin AVITA Medical since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's AVITA Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API
Get Free API Key

Margins — AVITA Medical

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — AVITA Medical